WEHI Special Blood Cells and Blood Cancer Seminar hosted by Professor Gemma Kelly

Associate Professor Lev Kats

Group Leader – Cancer Biology and Therapeutics Program, Peter MacCallum Cancer Centre

Targeting Menin in AML and beyond

 

Davis Auditorium

Join via TEAMS

Including Q&A session

With a focus on developing new therapeutic strategies to improve outcomes for blood cancer patients, our goal is to contribute along each stage of the biomedical research spectrum – from understanding fundamental oncogenic processes to identifying novel drug targets and investigating why cancer cells become resistant to established treatments. We use model systems and advanced molecular and functional genomic approaches to study how genetic events that are known to occur in human cancer alter the properties of blood cells. We are particularly interested in metabolic and epigenetic pathways that underpin cancer development and evolution.

Assoc Prof Lev Kats is a group leader within the Cancer Biology and Therapeutics Program and the co-lead of the Myeloma Medicines theme within the Barrie Dalgleish Centre for Myeloma and Related Blood Cancers. He was awarded his PhD in 2009 from Monash University and completed his post-doctoral training at Beth Israel Deaconess Centre/Harvard Medical School. Assoc Prof Kats is interested in epigenetic regulation, metabolism and targeted therapies and his laboratory uses molecular and functional genomics to develop new treatment strategies for aggressive blood cancers.

All welcome!